ReviewAvicenna journal of phytomedicine
Antioxidant, anti-inflammatory and cytoprotective effects of crocin, a bioactive constituent of saffron, in Alzheimer's and Parkinson's diseases with a focus on molecular mechanisms: A systematic review.
Review in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study assessed the neuroprotective effects of crocin one of the main bioactive compounds of saffron, in Alzheimer's and Parkinson's diseases, by focusing on its anti-oxidative, anti-inflammatory, and cytoprotective properties. Materials and Methods: In this systematic review, we evaluated the efficacy of crocin on Results: The total number of articles included in the present review is 28. Reducing reactive oxygen species (ROS) and malondialdehyde (MDA) and increasing superoxide dismutase (SOD) levels indicate the anti-oxidant effects of crocin. Crocin can show anti-inflammatory activities via decreasing tumor necrosis factor-alpha (TNF-α) and interleukin levels. Crocin can display cytoprotective effects via down-regulation of p- extracellular signal-regulated kinase (ERK)1/2, and augmentation of phosphoinositide 3-kinases (PI3K)/Akt/ mammalian target of rapamycin (mTOR) signaling pathway activity. Conclusion: Finally due to a noticeable efficacy of crocin, it is suggested that crocin can be used as a suitable neuroprotective agent against Alzheimer's and Parkinson's diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.